Table 1. Quantitation of LPA in plasma and serum.
Refer to references cited for experimental details. Values are from blood obtained from human sources unless otherwise noted. Plasma was obtained from blood anticoagulated with either citrate or EDTA
| Method | Plasma LPA Mean±SE (μM) | Serum LPA Mean/Range (μM) | Molecular Species (Plasma) | Notes | Reference |
|---|---|---|---|---|---|
| Radioenzymatic assay | 0.083±0.08 (Human) 0.17 ±0.05 (Mouse) | 0.28–0.71 (Fetal, Bovine) 1.31–2.56 (Donor, Bovine) | ND | Assay involves acylation of LPA catalysed by bacterial LPA acyltransferase using fatty acyl CoA of known specific radioactivity | Saulnier-Blache et al J. Lipid. Res. (2000) 41, 1947–1951. |
| Coupled Enzymatic Assay | 0.08±0.02(♂) 0.09±0.02(♀) | 0.41±0.14(♂) 0.41±0.12(♀) | ND | Assay involves lysophospholipase treatment and determination of glycerol 3-phosphate by an oxidase-coupled cycling reaction | Kishimoto et al (2003) Clin. Chem. Acta 33 59–67 |
| TLC-Gas Chromatography | 0.6±0.19(♀, Healthy) 14.9±3.22 (♀ Gynecologic Cancers | ND | 16:0, 18:0>18:1, 18:2, 20:4 | TLC purification, quantitation of fatty acid methyl esters | Xu et al JAMA 1998 280 719–723 Shen et al, Gyn. Onc. 83 25–30 |
| TLC/ESI/MS/MS | 0.9±0.43(♀, Healthy) 2.57 0.94(♀Ovarian I) 2.15 0.71(♀Ovarian II) 2.93 1.77(♀Ovarian III) 1.97 0.27 (♀Ovarian IV) | ND | 20:4>18:2, 18:1>18:0, 16:0>22:6 | TLC purification, direct infusion comparison of healthy controls with stage I-IV ovarian cancer patients | Sutphen et al (2004) Cancer Epidemiol. Biomarkers Prev. 13 1185–1191 |
| HPLC/ESI/MS | 0.61±0.14(♂ Fresh) 0.91±0.23 (♂, 24hrs, 25ºC) 0.74±0.17(♀, Fresh) 0.99± 0.38 (♀,24hrs, 25ºC) | 0.85±0.22(♂ Fresh) 1.57±0.56(♂, 24hrs, 25ºC) 4.78±0.89(♀, Fresh) 5.57±0.73(♀,24hrs, 25ºC) | 18:2>18:1>18: 0, 16:0, 20:4 | HPLC separation with LPA species identified by retention time and molecular m/z | Baker et al (2001) Anal. Biochem. 292, 287–295 |
| ESI/MS/MS | 4.3–5.0 (♀, Healthy) 7.9–8.7 (♀, Ovarian Cancer) | ND | 16:0>18:2>18: 0>18:1, 20:4 | Direct infusion of total lipid extracts | Yoon et. al. J. Chromatogaph. B. (2003) 85–92. |
| HPLC/ESI/MS/MS | ND | 2.9 (♀, Healthy) 8.4 (♀, Ovarian Cancer) | ND | No plasma measurements reported | Melah et. al. J. Chromatogaph. B. (2007) 287–291. |
| HPLC/ESI/MS/MS | 1.244±0.262 (♀, Healthy) 1.307±0.355 (♀, Benign) 1,224±0.386 (♀, Cancer) | ND | 16:0>18:2>20: 4>18:1>18:0 | Compared plasma LPA concentrations in healthy women to women with either benign or malignant breast tumors | Murph et. al. (2007) Methods Enzymol 433: 1–25 |
| HPLC/ESI/MS/MS | No pre-purification1.0–1.689 (♀, Healthy) 0.951–2.026 (♀, Cancer) TLC pre-purification 0.542–1.416 (♀, Healthy) 0.971–2.407 (♀, Cancer) | ND | 18:2>16:0, 20:4>18:1, 22:6, 18:0 | Compared plasma LPA concentrations in healthy women to those with ovarian cancer. Also examined effect of pre-purification of LPA by thin layer chromatography | Shan et. al. (2008) J. Chromatograph. B 864: 22–28. |